HollowellJG, StaehlingNW, FlandersWD, HannonWH, GunterEW, SpencerCA, BravermanLE. 2002. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab, 87:489–499.
Lillevang-JohansenM, AbrahamsenB, JørgensenHL, BrixTH, HegedüsL. 2019. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk. Thyroid, 29:332–340.
4.
WilliamsGR, BassettJHD. 2018. Thyroid diseases and bone health. J Endocrinol Invest, 41:99–109.
5.
RiebenC, SegnaD, da CostaBR, ColletTH, ChakerL, AubertCE, BaumgartnerC, AlmeidaOP, HogervorstE, TrompetS, MasakiK, MooijaartSP, GusseklooJ, PeetersRP, BauerDC, AujeskyD, RodondiN. 2016. Subclinical thyroid dysfunction and the risk of cognitive decline: a meta-analysis of prospective cohort studies. J Clin Endocrinol Metab, 101:4945–4954.
6.
AubertCE, BauerDC, da CostaBR, FellerM, RiebenC, SimonsickEM, YaffeK, RodondiN. 2017. The association between subclinical thyroid dysfunction and dementia: the Health, Aging and Body Composition (Health ABC) Study. Clin Endocrinol (Oxf), 87:617–626.
7.
FolkestadL, BrandtH, Lillevang-JohansenM, BrixT, HegedusL. 2020. Graves' disease and toxic nodular goiter, aggravated by duration of hyperthyroidism, and associated with Alzheimer's and vascular dementia. A register-based long-term follow-up of two large cohorts. Thyroid, 30:685–693.
8.
SamuelsMH. 2014. Thyroid disease and cognition. Endocrinol Metab Clin North Am, 96:223–233.
9.
ZhangW, SongL, YinX, ZhangJ, LiuC, WangJ, ZhouD, ChenB, LiiH. 2014. Grey matter abnormalities in untreated hyperthyroidism: a voxel-based morphometry study using the DARTEL approach. Eur J Radiol, 83:e43–e48.
10.
ZhangW, LiuX, ZhangY, SongL, HouJ, ChenB, HeM, CaiP, LiiH. 2014. Disrupted functional connectivity of the hippocampus in patients with hyperthyroidism: evidence from resting-state fMRI. Eur J Radiol, 83:1907–1913.
11.
ElberlingTV, DanielsenER, RasmussenAK, Feldt-RasmussenU, WaldemarG, ThomsenC. 2003. Reduced myo-inositol and total choline measured with cerebral MRS in acute thyrotoxic Graves' disease. Neurology, 60:142–145.
12.
LiuX, BaiZ, LiuF, LiM, ZhangQ, XuJ. 2012. Reduced posterior cingulate glutamate measured by magnetic resonance spectroscopy in hyperthyroidism. Neuro Endocrinol Lett, 33:626–630.
13.
MiaoQ, ZhangS, GuanYH, YeHY, ZhangZY, ZhangQY, XueRD, ZengMF, ZuoCT, LiYM. 2011. Reversible changes in brain glucose metabolism following thyroid function normalization in hyperthyroidism. AJNR Am J Neuroradiol, 32:1034–1042.
14.
GanEH, PearceSHS. 2012. The thyroid in mind: cognitive function and low thyrotropin in older people. J Clin Endocrinol Metab, 97:3438–3449.
15.
VillanuevaI, Alva-SanchezC, Pacheco-RosadoJ. 2013. The role of thyroid hormones as inductors of oxidative stress and neurodegeneration. Oxid Med Cell Long, 2013:218145.
16.
FuAL, ZhouCY, ChenX. 2010. Thyroid hormone prevents cognitive deficit in a mouse model of Alzheimer's disease. Neuropharmacology, 58:722–729.
17.
RossDS, BurchHB, CooperDS, GreenleeMC, LaurbergP, MaiaAL, RivkeesSA, SamuelsM, SosaJA, StanMN, WalterMA. 2016. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid, 26:1343–1421.
18.
BiondiB, BartalenaL, CooperDS, HegedüsL, LaurbergP, KahalyGJ. 2015. The 2015 European Thyroid Association guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J, 4:149–163.
